Protara Therapeutic
TARA4.0305.77% ( +0.220 )
Protara Therapeutic (TARA)
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare disea...
- Open
- 3.800
- High
- 4.045
- Low
- 3.771
- Prev. Close
- 3.810
- Volume
- 273.10K
- Turnover
- 1.08M
- Avg Price
- 3.971
- Bid/Ask Ratio
- --
- Amplitude
- 7.19%
- 52wk High
- 7.820
- Volume Ratio
- 0.65
- Turnover Ratio
- 0.56%
Protara Therapeutic Analyst Rating
View MoreForecast & Rating
Jun 30, 2026Price forecast
$26.57559.34%
Forecast & RatingStrong buy
8analysts
- Strong buy75.00%
- Buy25.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Jul 1 at 03:11 PM
Protara Therapeutics CEO Jesse Shefferman disposes of 215,687 common shares for $882,156.83
- PUBT · Jun 29 at 04:03 PM
Protara Therapeutics CMO Nicacio resigns effective June 26, 2026
- benzinga_article · May 15 at 10:36 AM
Protara Therapeutics Reports 55% Complete Response Rate In Bladder Cancer Study
- Tip Ranks · May 14 at 09:06 AM
Oppenheimer Keeps Their Buy Rating on Protara Therapeutics (TARA)
- Earnings Watch · May 13 at 07:07 AM
Protara Therapeutic | 8-K: FY2026 Q1 Revenue: USD 0
- Market Beat · May 7 at 03:06 AM
Protara Therapeutics (TARA) Projected to Post Quarterly Earnings on Thursday
